December 2016 Didn’t Deliver a Year-End Boost

The final month of the fourth quarter is typically a busy one for deal makers in all industries. Last year, some health care deal makers apparently got a rest. Deal volume in December 2016 was an anemic 119 transactions, compared with 131 deals in November and 148 in December 2015. The Services sectors accounted for 55% of the deals in December, which is on the low side. Consider that, in November, Services accounted for 69% of the month’s transactions, and even 70% of the total in December 2015. Spending on those deals reached $15.4 billion, a relatively modest amount until it is compared with November’s $8.7 billion total (+78%) and December 2015’s $12.3 billion total (+26%). Suddenly,... Read More »

Biotechnology Deals Will Surpass 2015’s Record

Deal volume in the Biotechnology sector is poised to surpass last year’s record-setting 160 transactions. With two weeks left in 2016, deal volume has reached 159 transactions. The activity in this sector shows no signs of abating, and will probably carry through the first half of 2017, at least. Big Pharma companies are driving the M&A activity, as they actively compete for promising drug candidates to bolster their aging pipelines. A case in point is a deal that hasn’t been announced yet, but that the industry is watching with interest. French pharma company Sanofi (NYSE: SNY) is reported to be deep into acquisition talks with Swiss biotech Actelion Ltd. (XETRA: ACT), and... Read More »